Answers are grounded in this paper and cite their sources.
To understand the distribution of daily doses of IPX203 in a phase 3 clinical study in Parkinson's disease (PD) patients exposed for at least 12 months, in terms of the doses that patients took most frequently (modal dose), and treatment emergent adverse events (TEAEs) by modal dose.
No takes yet. Share an insight, caveat, or question.
Ondo et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: